Tag: alpha-1 antitrypsin deficiency augmentation therapy market size

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market From 2025 To 2029?

The market size of augmentation therapy for alpha-1 antitrypsin deficiency has experienced robust growth lately. Projected to rise from $1.69 billion in 2024 to $1.8 billion in 2025, it is expected to witness a compound annual growth rate (CAGR) of 6.2%. The significant surge in the historical period is primarily due to better diagnostic procedures, consciousness drives, clinical studies, and an ageing population.

There is anticipated robust expansion in the alpha-1 antitrypsin deficiency augmentation therapy market size over the forthcoming years, projecting a growth to$2.44 billion in 2029, at a compound annual growth rate (CAGR) of 7.9%. The predicted growth during the forecast period can be traced back to advancements and developments in telehealth, remote monitoring, precision medicine, and gene therapy. The forthcoming period is also expected to witness significant trends such as the accumulation of long-term safety and efficacy data, the adoption of patient-centered care models, tele-rehabilitation programs, and personalized dosing regimens.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

Which Primay Drivers Are Accelerating Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

The alpha-1 antitrypsin deficiency augmentation therapy market is experiencing growth due to a rise in respiratory illnesses. These are disorders that impact the lungs and respiratory system, causing difficulty breathing and reduced lung performance. This therapy aims to treat such diseases by supplementing the insufficient protein in individuals suffering from alpha-1 antitrypsin deficiency. The approach corrects the protease-antiprotease imbalance in the lungs, shielding lung tissue from damage due to unchecked neutrophil elastase activity and alleviating inflammation. For example, the Centers for Disease Control and Prevention, a US-based nationwide public health body, reported in March 2023 that there were 8,300 tuberculosis (TB) cases in the US in 2022, a surge from 7,874 cases in 2021. Hence, the escalating number of respiratory illnesses is fueling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Which Primary Segments of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Are Driving Growth and Industry Transformations?

The alpha-1 antitrypsin deficiency augmentation therapymarket covered in this report is segmented –

1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza

2) By Route Of Administration: Oral; Injection; Inhalation

3) By End User: Hospitals; Specialty Clinics; Other End Users

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?# Market?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Dynamics?

In an effort to maintain their market dominance in the acute respiratory distress syndrome (ARDS) sector, leading businesses are concentrating their energies on the invention of new therapeutic approaches, such as recombinant technology-based drug development. Utilizing recombinant DNA technology enables these companies to modify the DNA of living organisms to produce specific proteins, thereby creating pharmaceutical therapeutics. For instance, Inhibrx Inc., a US biotech firm, revealed in March 2022, that their product INBRX-101 had attained orphan drug status from the U.S. Food and Drug Administration (FDA) for addressing alpha-1 antitrypsin deficiency (AATD). INBRX-101, a recombinant human AAT-Fc fusion protein, that could potentially deliver a once-monthly dosage, is designed to safely reach and sustain AAT levels in line with those found in healthy individuals.

View the full report here:

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

What Parameters Are Used to Define the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market from 2024 to 2025?

Recently, the alpha-1 antitrypsin deficiency augmentation therapy market has experienced robust growth. The market size is projected to increase from $1.69 billion in 2024 to $1.82 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Factors such as better diagnostic procedures, awareness programs, clinical studies, and an aging population have fueled this growth in the historical period.

What Is the Projected Market Size of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

The market for alpha-1 antitrypsin deficiency augmentation therapy is projected to experience noteworthy expansion in the upcoming years, reaching a value of $2.47 billion in 2029 with an annual growth rate of 7.9%. This growth over the forecast period is mainly due to advances in telehealth and remote monitoring, precision medicine, and gene therapy. Expected trends to shape this duration include the constant data on security and effectiveness, focus on patient-oriented care models, tele-rehabilitation programs, and individualized dosage plans.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

Who are the Major Competitors in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Outlook?

Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

What Is Fueling Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

The surge in respiratory ailments fosters the escalation of the alpha-1 antitrypsin deficiency augmentation therapy market. Afflictions impeding lung and respiratory system functions lead to breathing complications and lung function impairment. The therapy designed to alleviate respiratory diseases in patients suffering from alpha-1 antitrypsin deficiency replenishes the deficient protein. Its mechanism involves re-establishing the protease-antiprotease activity balance within the lungs, shielding the lung tissue against injury resulting from excessive neutrophil elastase activity, thereby curtailing inflammation. For example, the Centers for Disease Control and Prevention, a US national public health establishment, reported that the US recorded 8,300 cases of tuberculosis (TB) in March 2023, rising from 7,874 instances in 2021. Therefore, the escalating number of respiratory ailments fuels the alpha-1 antitrypsin deficiency augmentation therapy market expansion. The anticipated boost of the alpha-1 antitrypsin deficiency augmentation therapy market is due to an upsurge in clinical trials. Clinical trials involve biomedical or behavioural research studies carried out on humans to provide answers to specific queries about biomedical or behavioural interventions, which encompasses new treatments and previously known interventions that merit further study and comparison. Such trials play a critical role in formulating and authorising new AATD therapies and drugs. The rise in clinical trial numbers indicates growing enthusiasm towards developing novel AATD therapies, which could lead to the launch of new and more efficient treatments in the market. For instance, as per a report released by Xtalks, a Canada-based web news and information network in May 2023, the number of clinical studies registered on ClinicalTrials.gov stood at 452,604, a considerable increase from over 365,000 trials recorded in early 2021. As a result, the alpha-1 antitrypsin deficiency augmentation therapy market is stimulated by the increase in clinical trials.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp

Which Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segments Are Growing the Fastest?

The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza

2) By Route Of Administration: Oral, Injection, Inhalation

3) By End User: Hospitals, Specialty Clinics, Other End Users

Which Industry Trends Are Shaping the Future of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

Major firms in the acute respiratory distress syndrome (ARDS) market are concentrating on creating innovative treatments, such as recombinant technology-based drug development, in order to maintain their standing in the market. The process of manufacturing recombinant technology-based therapeutics involves the modification of a live organism’s DNA to produce specific proteins. For example, Inhibrx Inc., a biotechnology company from the US, announced in March 2022 that its INBRX-101 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for alpha-1 antitrypsin deficiency (AATD) treatment. INBRX-101, which is a recombinant human AAT-Fc fusion protein, potentially needs to be administered only once a month. It aims to safely achieve and maintain the levels of AAT found in healthy individuals.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Which Countries Are Leading the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006

This Report Delivers Insight On:

1. How big is the alpha-1 antitrypsin deficiency augmentation therapy market, and how is it changing globally?

2. Who are the major companies in the alpha-1 antitrypsin deficiency augmentation therapy market, and how are they performing?

3. What are the key opportunities and risks in the alpha-1 antitrypsin deficiency augmentation therapy market right now?

4. Which products or customer segments are growing the most in the alpha-1 antitrypsin deficiency augmentation therapy market?

5. What factors are helping or slowing down the growth of the alpha-1 antitrypsin deficiency augmentation therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the alpha-1 antitrypsin deficiency augmentation therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Milestones in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market’s Growth Trajectory From 2025 To 2034?

The market size of alpha-1 antitrypsin deficiency augmentation therapy has witnessed robust growth in the past few years. It is projected to expand from $1.69 billion in 2024 to $1.82 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historic period can be associated with better diagnosis techniques, awareness drives, clinical studies, and an increasing aging population.

The market for alpha-1 antitrypsin deficiency augmentation therapy is projected to see a substantial increase in the coming years, reaching a size of $2.47 billion in the year 2029 at a compound annual growth rate (CAGR) of 7.9%. The significant growth anticipated within the forecast period is largely due to advancements in telehealth and remote monitoring, precision medicine, and gene therapy. The forecast period is expected to witness key trends like long-term safety and efficacy data, patient-focused care models, tele-rehabilitation initiatives, and customized dosing schemes.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

What Are the Core Market Drivers Propelling Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry?

The growth of the alpha-1 antitrypsin deficiency augmentation therapy market is being pushed by an uptick in respiratory diseases. Disorders impairing the lungs and respiratory system contribute to breathing disruptions and reduced lung functionality, which are addressed through this therapy. The therapy enhances the necessary proteins in individuals suffering from alpha-1 antitrypsin deficiency, restoring the balance in the lungs, providing protection against excessive neutrophil elastase activity and curbing inflammation. The Centers for Disease Control and Prevention noted in March 2023 that there were 8,300 cases of tuberculosis in the US in 2022, up from 7,874 in 2021. As such, the escalating number of respiratory ailments is further propelling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. The alpha-1 antitrypsin deficiency augmentation therapy market is also set to grow due to the rise in the number of clinical trials, a critical component in the development and approval of new drugs and therapies for AATD. These trials, whether biomedical or behavioral, aim to answer critical questions regarding new and existing interventions. The growing interest in crafting new treatments for AATD is evident in the mounting number of clinical studies, increasing the probability of better, more efficient therapies entering the market. Remarkably, a May 2023 report by Canada’s Xtalks disclosed that over 452,604 clinical trials had been registered on ClinicalTrials.gov, highlighting a significant increase from the early 2021 tally of over 365,000 registered trials. Consequently, the uptrend in the number of clinical trials boosts the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

How Is the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segmented?

The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza

2) By Route Of Administration: Oral, Injection, Inhalation

3) By End User: Hospitals, Specialty Clinics, Other End Users

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp

Which Regions Are Driving the Next Phase of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry?

Leading corporations in the acute respiratory distress syndrome (ARDS) market are striving to create innovative therapies, such as drugs developed with recombinant technology, to maintain their market dominance. This technique involves altering the DNA of living organisms to produce specific proteins and is used for manufacturing therapeutic pharmaceutical products. For example, in March 2022, the biotech firm Inhibrx Inc., based in the US, revealed that their product, INBRX-101, was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101, a recombinant human AAT-Fc fusion protein, with the possibility of a once-monthly dose, aims to safely achieve and sustain the AAT levels found in healthy individuals.

View the full report here:

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

How Is the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Defined and What Are Its Core Parameters?

Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theAlpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

The rise in respiratory diseases is fueling the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. Conditions affecting the lungs and respiratory system can often result in breathing difficulties and reduced lung function. The goal of alpha-1 antitrypsin deficiency augmentation therapy is to alleviate these respiratory diseases by complementing the deficient protein in those with alpha-1 antitrypsin deficiency. This therapy functions by reestablishing protease-antiprotease activity balance within the lungs, defending lung tissue against harm resulting from excessive neutrophil elastase activity and minimizing inflammation. For instance, the Centers for Disease Control and Prevention reported that in March 2023, there were 8,300 tuberculosis cases in the United States, signifying a rise from 7,874 cases in 2021. Hence, the increase in respiratory diseases is boosting the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. The upswing in clinical trials is foreseen to catalyze the growth of the alpha-1 antitrypsin deficiency augmentation therapy market in the future. Clinical trials are biomedical or behavioral research studies involving human subjects designed to answer specific questions about biomedical or behavioral interventions, encompassing new treatments and known interventions that need additional study and comparison. These trials play a critical role in developing and approving new treatments and medications for AATD. The growth in clinical trials suggests heightened interest in developing new therapies for AATD, which could result in bringing new and better treatments to the market. For example, as per a report by Xtalks, a Canadian web news and information network, in May 2023, 452,604 clinical studies were registered at ClinicalTrials.gov. This represents an impressive surge from over 365,000 registered trials in early 2021. Therefore, the increased number of clinical trials is fueling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

#How Will the CAGR of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Influence Its Overall Growth by 2034?

In recent times, the market for alpha-1 antitrypsin deficiency augmentation therapy has experienced substantial growth. The market is predicted to expand from $1.69 billion in 2024 to $1.82 billion in 2025 representing a compound annual growth rate (CAGR) of 7.3%. The surge in growth during the historical period can be accredited to heightened diagnosis, awareness drives, clinical studies, and an aging populace.

In the forthcoming years, the market size of augmentation therapy for alpha-1 antitrypsin deficiency is anticipated to experience robust expansion. It is projected to escalate to $2.47 billion in 2029, with a compound annual growth rate (CAGR) of 7.9%. The projected growth during this period is attributed to advancements in telehealth, remote monitoring, precision medicine, and gene therapy. Significant trends anticipated during this period include data on long-term safety and efficacy, models of patient-centred care, tele-rehabilitation programs, and personalised dosing regimens.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006

What Key Market Trends and Innovations Are Shaping the Future of theAlpha-1 Antitrypsin Deficiency Augmentation Therapy Industry?

Prominent players in the acute respiratory distress syndrome (ARDS) market are concentrating on developing cutting-edge therapies, such as those based on recombinant technology, to maintain their industry standing. The method involves the utilization of recombinant DNA technology to create therapeutic pharmaceuticals. This technique encompasses the alteration of live organism’s DNA to produce specific proteins. For example, in March 2022, Inhibrx Inc, an American biotechnology firm, declared that the U.S. Food and Drug Administration (FDA) has bestowed orphan drug designation to INBRX-101 for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a fusion protein of recombinant human AAT-Fc that has the potential for a single monthly dosage. Its goal is to safely achieve and maintain AAT levels akin to those found in healthy individuals.

Which Companies Are Leading the Charge in Expanding theAlpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth?

Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

How is the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segemented?

The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza

2) By Route Of Administration: Oral, Injection, Inhalation

3) By End User: Hospitals, Specialty Clinics, Other End Users

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp

Which Geographics are Influencing the Growth of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 2025, By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

TNF Alpha Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the alpha-1 antitrypsin deficiency augmentation therapy market grown in recent years?

The market size for alpha-1 antitrypsin deficiency augmentation therapy has seen considerable growth recently. It’s projected to escalate from $1.69 billion in 2024 to $1.82 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%. Reasons for this expansion during the historical period can be traced back to enhancements in diagnosis, proliferation of awareness campaigns, advances in clinical research, and an aging demographic.

How is the alpha-1 antitrypsin deficiency augmentation therapy market size expected to evolve during the forecast period?

The market size for alpha-1 antitrypsin deficiency augmentation therapy is predicted to experience robust expansion in the approaching years. By 2029, it is predicted to reach a value of $2.47 billion, achieving a 7.9% Compound Annual Growth Rate (CAGR). The anticipated growth could be attributed to advancements in telehealth, remote monitoring, precision medicine, and gene therapy. Significant trends foreseen during this period could include the availability of long-term safety and efficacy data, the use of patient-centric care models, the implementation of tele-rehabilitation programs, and the application of personalized dosing regimens.

Get your alpha-1 antitrypsin deficiency augmentation therapy market report here!

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Which key drivers are propelling the alpha-1 antitrypsin deficiency augmentation therapy market’s growth?

The rise in respiratory diseases is fueling the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. These diseases, which impair lung function and lead to breathing problems, are countered by this therapy. It works by supplementing the insufficient protein in people with alpha-1 antitrypsin deficiency, bolstering protease-antiprotease activity balance in the lungs, reducing inflammation, and safeguarding lung tissue from excessive neutrophil elastase activity damage. For instance, the Centers for Disease Control and Prevention reported in March 2023 that the United States saw an increase in tuberculosis cases from 7,874 in 2021 to 8,300 in 2022. Thus, the surge in respiratory diseases is fuelling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Regarding the alpha-1 antitrypsin deficiency augmentation therapy market driver, growth is predicted to be fueled by an increase in clinical trials. Clinical trials, which are biomedical or behavioral research studies conducted on humans to answer specific questions about interventions, are important for developing and approving new AATD treatments. The rise in the number of these trials suggests an increased interest in AATD therapy development, which could bring new and more effective treatments to market. For example, in May 2023, Xtalks, a Canada-based news and information network, reported that the number of clinical studies registered on ClinicalTrials.gov had grown significantly from over 365,000 early in 2021 to 452,604 by May 2023. Consequently, the increase in clinical trials is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

What are the market segments in the alpha-1 antitrypsin deficiency augmentation therapy industry?

The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza

2) By Route Of Administration: Oral, Injection, Inhalation

3) By End User: Hospitals, Specialty Clinics, Other End Users

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

Which leading companies are shaping the growth of the alpha-1 antitrypsin deficiency augmentation therapy market?

Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

What key trends are currently impacting the alpha-1 antitrypsin deficiency augmentation therapy market’s development?

Leading firms in the acute respiratory distress syndrome (ARDS) industry are prioritizing the creation of novel therapies, such as drug development based on recombinant technology, to maintain their standing in the market. Recombinant DNA technology is utilized to create therapeutic pharmaceuticals through modification of live organisms’ DNA to produce specific proteins. For example, Inhibrx Inc., a biotechnology company situated in the US, disclosed in March 2022 that INBRX-101, a recombinant human AAT-Fc fusion protein with a potential once-monthly dosage schedule, secured an orphan drug status from the U.S. Food and Drug Administration (FDA) for the treatment of alpha-1 antitrypsin deficiency (AATD). The aim of INBRX-101 is to safely achieve and sustain the AAT levels observed in healthy persons.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006

Which geographic areas are influencing the growth of the alpha-1 antitrypsin deficiency augmentation therapy market?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

TNF Alpha Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The market of alpha-1 antitrypsin deficiency augmentation therapy has witnessed robust expansion in the past few years. Its size is projected to escalate from $1.69 billion in 2024 to $1.82 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.3%. Factors such as enhanced diagnostic procedures, public awareness drives, clinical research, and the rise in the ageing population have contributed to its growth in the preceding period.

There is an anticipated firm growth in the alpha-1 antitrypsin deficiency augmentation therapy market size over the next several years. With a compound annual growth rate (CAGR) of 7.9%, it is projected to increase to $2.47 billion by 2029. Contributing factors to this growth throughout the projected period are advancements in telehealth and remote monitoring, precision medicine, and gene therapy. Key trends for this period consist of data related to long-term safety and effectiveness, models of care centered around the patient, programs of tele-rehabilitation, and personalized dosing regimens.

How Are the key drivers expanding the growth of the alpha-1 antitrypsin deficiency augmentation therapy Market?

The escalation in the occurrence of respiratory diseases is considered a significant factor contributing to the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. These diseases, which impact the lungs and respiratory system, result in chaotic breathing and a diminished lung function. The purpose of alpha-1 antitrypsin deficiency augmentation therapy is to remediate these diseases by supplementing the insufficient protein in those suffering from alpha-1 antitrypsin deficiency. This therapy attains this by normalizing protease-antiprotease activity in the lungs, safeguarding lung tissue from harm induced by heightened neutrophil elastase activity, and the reduction of inflammation. As an illustration, the United States reported a rise in tuberculosis (TB) cases from 7,874 in 2021 to 8,300 in 2022, as stated by the Centers for Disease Control and Prevention in March 2023. Consequently, the surge in respiratory diseases has led to a robust growth for the alpha-1 antitrypsin deficiency augmentation therapy market. Growth in the alpha-1 antitrypsin deficiency augmentation therapy market is expected due to a rise in the number of clinical trials. Clinical trials are forms of research, using human participants, that explore and compare biomedical or behavioral interventions, including new and known treatments, to answer essential health-related questions. Critical to the creation and authorization of unique treatments for AATD, an increase in clinical trials illustrates an uptick in the interest in developing novel therapies for AATD. This could result in the emergence of improved treatments. In May 2023, Xtalks, a Canada-based news and information network, reported 452,604 clinical studies registered on ClinicalTrials.gov, a significant increase from just over 365,000 in 2021. This spike in the number of clinical trials makes a compelling case for the anticipated growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Get Your Free Sample of the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

Who Are the Influential Players Reshaping the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Landscape?

Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are:

• Pfizer Inc._x000D_

• Sanofi S.A._x000D_

• AstraZeneca PLC_x000D_

• GlaxoSmithKline PLC_x000D_

• Takeda Pharmaceutical Company Limited_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

Leading enterprises in the acute respiratory distress syndrome (ARDS) market are strategically focusing on the development of novel therapies, such as those based on recombinant technology, in order to preserve their market standing. Recombinant DNA technology is employed for the generation of therapeutic drugs via recombinant technology-based drug development. This process involves the alteration of DNA in living organisms to create specific proteins. For example, Inhibrx Inc., a biotechnology firm based in the US, announced in March 2022 that INBRX-101 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the management of alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein that may enable a once-monthly dosage and is expected to safely attain and maintain AAT levels consistent with those of healthy individuals.

Get Instant Access to the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

How Are the Key Segments of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Impacting Its Expansion and Revenue Streams?

The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza

2) By Route Of Administration: Oral, Injection, Inhalation

3) By End User: Hospitals, Specialty Clinics, Other End Users

Which Geographic Locations Are Critical to the Growth of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Key Characteristics That Define the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

TNF Alpha Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: